Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
< or =,8730924,mean residence time,"2. After intravenous administration the mean residence time was < or = 1.5 h in all species, and the plasma clearance approached the corresponding hepatic blood flows.","Pharmacokinetics of remikiren, a potent orally active inhibitor of human renin, in rat, dog and primates. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730924/),h,1.5,51646,DB00212,Remikiren
<,8730924,oral bioavailability,"4. Consistent with the high hepatic clearance, oral bioavailability was low ( < or = 6%) in each species.","Pharmacokinetics of remikiren, a potent orally active inhibitor of human renin, in rat, dog and primates. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730924/),%,or,51647,DB00212,Remikiren
<,8730924,oral bioavailability,"4. Consistent with the high hepatic clearance, oral bioavailability was low ( < or = 6%) in each species.","Pharmacokinetics of remikiren, a potent orally active inhibitor of human renin, in rat, dog and primates. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730924/),%,6,51648,DB00212,Remikiren
,10720595,terminal half-life (T1/2beta),The terminal half-life (T1/2beta) was increased (130 versus 82 minutes) and the metabolic clearance rate (MCR) was decreased (0.83+/-0.29 versus 2.2+/-0.66 microL. min(-1).,Angiotensinogen concentrations and renin clearance : implications for blood pressure regulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10720595/),min,130,93768,DB00212,Remikiren
,10720595,terminal half-life (T1/2beta),The terminal half-life (T1/2beta) was increased (130 versus 82 minutes) and the metabolic clearance rate (MCR) was decreased (0.83+/-0.29 versus 2.2+/-0.66 microL. min(-1).,Angiotensinogen concentrations and renin clearance : implications for blood pressure regulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10720595/),min,82,93769,DB00212,Remikiren
,10720595,metabolic clearance rate (MCR),The terminal half-life (T1/2beta) was increased (130 versus 82 minutes) and the metabolic clearance rate (MCR) was decreased (0.83+/-0.29 versus 2.2+/-0.66 microL. min(-1).,Angiotensinogen concentrations and renin clearance : implications for blood pressure regulation. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10720595/),[μl] / [min],0.83,93770,DB00212,Remikiren
,10720595,metabolic clearance rate (MCR),The terminal half-life (T1/2beta) was increased (130 versus 82 minutes) and the metabolic clearance rate (MCR) was decreased (0.83+/-0.29 versus 2.2+/-0.66 microL. min(-1).,Angiotensinogen concentrations and renin clearance : implications for blood pressure regulation. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10720595/),[μl] / [min],2.2,93771,DB00212,Remikiren
,1282588,Drug concentration peaked,Drug concentration peaked (482 +/- 140 ng/ml) at the end of the fast infusion or showed a sustained plateau (25.9 +/- 6.1 ng/ml) with the slow infusion (mean time to peak 121 +/- 99 min).,"Neurohormonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42-5892, in salt-replete men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282588/),[ng] / [ml],482,203915,DB00212,Remikiren
,1282588,Drug concentration peaked,Drug concentration peaked (482 +/- 140 ng/ml) at the end of the fast infusion or showed a sustained plateau (25.9 +/- 6.1 ng/ml) with the slow infusion (mean time to peak 121 +/- 99 min).,"Neurohormonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42-5892, in salt-replete men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282588/),[ng] / [ml],25.9,203916,DB00212,Remikiren
,1282588,time to peak,Drug concentration peaked (482 +/- 140 ng/ml) at the end of the fast infusion or showed a sustained plateau (25.9 +/- 6.1 ng/ml) with the slow infusion (mean time to peak 121 +/- 99 min).,"Neurohormonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42-5892, in salt-replete men. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282588/),min,121,203917,DB00212,Remikiren
,1282588,area under the curve (,Both fast (135.2 +/- 26 ng/ml/h2) and slow (121.0 +/- 31.1 ng/ml/h2) infusions had similar area under the curve (AUC)0-24-values.,"Neurohormonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42-5892, in salt-replete men. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282588/),[ng] / [h2·ml],121.0,203918,DB00212,Remikiren
,1282588,AUC0-10,"Plasma renin activity (PRA) was dramatically reduced by both strategies, but AUC0-10 for PRA was significantly less for slow (1.7 +/- 0.6 ngAI/ml/h2) than fast (4.9 +/- 2.5 ngAI/ml/h2) infusions.","Neurohormonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42-5892, in salt-replete men. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282588/),[ngai] / [h2·ml],1.7,203919,DB00212,Remikiren
,1282588,AUC0-10,"Plasma renin activity (PRA) was dramatically reduced by both strategies, but AUC0-10 for PRA was significantly less for slow (1.7 +/- 0.6 ngAI/ml/h2) than fast (4.9 +/- 2.5 ngAI/ml/h2) infusions.","Neurohormonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42-5892, in salt-replete men. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282588/),[ngai] / [h2·ml],4.9,203920,DB00212,Remikiren
,1282588,peak plasma active renin (AR) concentration,Mean peak plasma active renin (AR) concentration was increased by both fast (102.2 +/- 65.9 pg/ml) and slow (195.2 +/- 110.5 pg/ml) infusions as compared with placebo (49.9 +/- 18.6 pg/ml).,"Neurohormonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42-5892, in salt-replete men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282588/),[pg] / [ml],102.2,203921,DB00212,Remikiren
,1282588,peak plasma active renin (AR) concentration,Mean peak plasma active renin (AR) concentration was increased by both fast (102.2 +/- 65.9 pg/ml) and slow (195.2 +/- 110.5 pg/ml) infusions as compared with placebo (49.9 +/- 18.6 pg/ml).,"Neurohormonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42-5892, in salt-replete men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282588/),[pg] / [ml],195.2,203922,DB00212,Remikiren
,1282588,peak plasma active renin (AR) concentration,Mean peak plasma active renin (AR) concentration was increased by both fast (102.2 +/- 65.9 pg/ml) and slow (195.2 +/- 110.5 pg/ml) infusions as compared with placebo (49.9 +/- 18.6 pg/ml).,"Neurohormonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42-5892, in salt-replete men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282588/),[pg] / [ml],49.9,203923,DB00212,Remikiren
,1282588,AUC0-10,"Similarly, AUC0-10 for AR was greater for slow (990.2 +/- 582.1 pg/ml/h) than fast (512.4 +/- 189.4 pg/ml/h) infusions.","Neurohormonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42-5892, in salt-replete men. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282588/),[pg] / [h·ml],990.2,203924,DB00212,Remikiren
,1282588,AUC0-10,"Similarly, AUC0-10 for AR was greater for slow (990.2 +/- 582.1 pg/ml/h) than fast (512.4 +/- 189.4 pg/ml/h) infusions.","Neurohormonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42-5892, in salt-replete men. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282588/),[pg] / [h·ml],512.4,203925,DB00212,Remikiren
,12959271,Cmax,"Mean Cmax values (on the first and last day of oral treatment) were in the magnitude of 4-6 ng ml(-1) (200 mg), 23-27 ng ml(-1) (300 mg), 65-83 ng ml(-1) (600 mg) and 47-48 ng ml(-1) (800 mg).",Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959271/),[ng] / [ml],4-6,221904,DB00212,Remikiren
,12959271,Cmax,"Mean Cmax values (on the first and last day of oral treatment) were in the magnitude of 4-6 ng ml(-1) (200 mg), 23-27 ng ml(-1) (300 mg), 65-83 ng ml(-1) (600 mg) and 47-48 ng ml(-1) (800 mg).",Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959271/),[ng] / [ml],23-27,221905,DB00212,Remikiren
,12959271,Cmax,"Mean Cmax values (on the first and last day of oral treatment) were in the magnitude of 4-6 ng ml(-1) (200 mg), 23-27 ng ml(-1) (300 mg), 65-83 ng ml(-1) (600 mg) and 47-48 ng ml(-1) (800 mg).",Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959271/),[ng] / [ml],65-83,221906,DB00212,Remikiren
,12959271,Cmax,"Mean Cmax values (on the first and last day of oral treatment) were in the magnitude of 4-6 ng ml(-1) (200 mg), 23-27 ng ml(-1) (300 mg), 65-83 ng ml(-1) (600 mg) and 47-48 ng ml(-1) (800 mg).",Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959271/),[ng] / [ml],47-48,221907,DB00212,Remikiren
,12959271,IC50,An IC50 value of 0.5 ng ml(-1) (0.8 nM) was estimated.,Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959271/),[ng] / [ml],0.5,221908,DB00212,Remikiren
,12959271,IC50,An IC50 value of 0.5 ng ml(-1) (0.8 nM) was estimated.,Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959271/),nM,0.8,221909,DB00212,Remikiren
,7795817,extraction recovery,The extraction recovery of Ro 42-5892 from human plasma (mean 102%) was quantitative.,"Determination of the renin inhibitor Ro 42-5892 in human plasma by automated pre-column derivatization, reversed-phase high-performance liquid chromatographic separation and electrochemical detection after post-column irradiation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7795817/),%,102,229774,DB00212,Remikiren
,7795817,limit of quantitation,With this method a limit of quantitation of 0.3 ng/ml was achieved.,"Determination of the renin inhibitor Ro 42-5892 in human plasma by automated pre-column derivatization, reversed-phase high-performance liquid chromatographic separation and electrochemical detection after post-column irradiation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7795817/),[ng] / [ml],0.3,229775,DB00212,Remikiren
,8491068,Systemic plasma clearance,"Systemic plasma clearance, volume of distribution, and absolute bioavailability of remikiren were in the magnitude of 900 ml/min, 70 L, and below 1%, respectively.","Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491068/),[ml] / [min],900,263380,DB00212,Remikiren
,8491068,volume of distribution,"Systemic plasma clearance, volume of distribution, and absolute bioavailability of remikiren were in the magnitude of 900 ml/min, 70 L, and below 1%, respectively.","Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491068/),l,70,263381,DB00212,Remikiren
,8491068,absolute bioavailability,"Systemic plasma clearance, volume of distribution, and absolute bioavailability of remikiren were in the magnitude of 900 ml/min, 70 L, and below 1%, respectively.","Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491068/),%,1,263382,DB00212,Remikiren
